Century Therapeutics, Inc. (IPSC) — Financial statements
Income statement, balance sheet, and cash flow for Century Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 109↑1556.8% | 7↑194.8% | 2↓57.0% | 5 | 0.00 | |
| Cost of Revenue | 13 | 0.00 | 0.00 | 0.00↓100.0% | 5 | |
| Gross Profit | 96↑1357.9% | 7↑194.8% | 2↓57.0% | 5↑213.5% | -5 | |
| Operating Expenses | ||||||
| R&D Expenses | 96↓10.8% | 107↑15.7% | 93↓4.6% | 97↑28.5% | 76 | |
| General & Administrative Expenses | 24↓27.6% | 33↓4.5% | 35↑8.9% | 32 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↓27.6% | 33↓4.5% | 35↑8.9% | 32↑117.4% | 15 | |
| Other Expenses | -9↓298.0% | 4↓79.7% | 21↑113.7% | 10 | 0.00 | |
| Operating Expenses | 111↓23.2% | 145↓2.7% | 149↑7.0% | 139↑54.0% | 90 | |
| Total Costs & Expenses | 124↓14.2% | 145↓2.7% | 149↑7.0% | 139↑46.5% | 95 | |
| Operating Results | ||||||
| Operating Income | -15↑89.1% | -138↑5.7% | -147↓9.5% | -134↓41.0% | -95 | |
| Depreciation & Amortization | 13↓1.5% | 13↑2.0% | 13↑54.5% | 8↑84.2% | 5 | |
| EBITDA | -2↑98.3% | -111↑8.0% | -121↓0.0% | -121↓34.8% | -90 | |
| EBIT | -15↑87.9% | -125↑7.1% | -134↓3.6% | -130↓37.2% | -95 | |
| Interest & Other Income | ||||||
| Net Interest Income | 7↓43.5% | 13↑7.2% | 12↑305.9% | 3↑893.1% | -0.38 | |
| Interest Income | 7↓43.5% | 13↑2.6% | 13↑324.0% | 3↑233.0% | 0.90 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.54 | 0.00↓100.0% | 1 | |
| Non-Operating Income | 0.00↑100.0% | -13↓8.7% | -12↓193.4% | -4↓1011.4% | -0.38 | |
| Other Income / Expenses | 5↓59.6% | 13↑13.7% | 12↑293.1% | 3↑433.0% | -0.90 | |
| Income Before Tax | -10↑92.3% | -125↑7.4% | -135↓3.0% | -131↓36.6% | -96 | |
| Income Tax Expense | -0.07↓103.8% | 2↓4.8% | 2↑1967.0% | 0.09↑111.6% | 0.04 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -10↑92.4% | -127↑7.4% | -137↓4.4% | -131↓36.6% | -96 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -10↑92.4% | -127↑7.4% | -137↓4.4% | -131↓36.6% | -96 | |
| Bottom-Line Net Income | -10↑92.4% | -127↑7.4% | -137↓4.4% | -131↓36.6% | -96 | |
| EPS (Basic) | -0.11↑93.2% | -1.61↑30.0% | -2.30↓1.3% | -2.27↓30.5% | -1.74 | |
| EPS (Diluted) | -0.11↑93.2% | -1.61↑30.0% | -2.30↓1.3% | -2.27↓30.5% | -1.74 | |
| Weighted Average Shares | 87↑10.1% | 79↑32.6% | 59↑2.7% | 58↑5.0% | 55 | |
| Weighted Average Diluted Shares | 87↑10.1% | 79↑32.6% | 59↑2.7% | 58↑5.0% | 55 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.